key: cord-0991191-c2tj6cy6 authors: Cordtz, René; Kristensen, Salome; Westermann, Rasmus; Duch, Kirsten; Pearce, Fiona; Lindhardsen, Jesper; Torp-Pedersen, Christian; Andersen, Mikkel P; Dreyer, Lene title: COVID-19 infection and hospitalisation risk according to vaccination status and DMARD treatment in patients with rheumatoid arthritis date: 2022-04-13 journal: Rheumatology (Oxford) DOI: 10.1093/rheumatology/keac241 sha: 958d480fb34174f61cc0b1de22e380c4a56f0fdd doc_id: 991191 cord_uid: c2tj6cy6 OBJECTIVES: To investigate the incidence of COVID-19 hospitalisation in unvaccinated and vaccinated patients with rheumatoid arthritis (RA) compared with matched controls, and in patients with RA according to DMARD treatment. METHODS: Danish nationwide matched cohort study from January to October 2021. Patients with RA were identified in the DANBIO register and matched 1:20 with individuals from the general population on age, sex, and vaccination status. Primary and secondary outcomes were COVID-19 hospitalisation (Danish National Patient Register) and first-time positive SARS-CoV2 PCR test (Danish COVID-19 Surveillance Register), respectively. Stratified by vaccination status, incidence rates (IRs) per 1000 person years (PY) and comorbidity-adjusted hazard ratios (aHRs) in cause-specific Cox models were calculated with 95% confidence intervals. RESULTS: In total, 28 447 unvaccinated patients and 568 940 comparators had Irs for COVID-19 hospitalisation of 10.4 (8.0–13.4) and 4.7 (4.3–5.1) per 1000 PY, respectively (aHR 1.88, 1.44–2.46). When fully vaccinated, corresponding Irs were 0.9 (0.5–1.6) and 0.5 (0.4–0.6) per 1000 PY (aHR 1.94, 1.03–3.66). Unvaccinated RA patients had an aHR of 1.22 (1.09–1.57) for testing positive for SARS-CoV2 and 1.09 (0.92–1.14) among vaccinated. Vaccinated rituximab-treated patients had increased crude IR of COVID-19 hospitalisation compared with conventional DMARD treated patients. CONCLUSION: The incidence of COVID-19 hospitalisation was increased for both unvaccinated and vaccinated patients with RA compared with controls. Importantly, the parallel decreasing risk for patients with RA suggests a comparable relative benefit of vaccination in most patients. -Regardless of vaccination, risk of COVID-19 hospitalisation was increased in patients with rheumatoid arthritis. -The absolute risk of hospitalisation was, however, markedly lower among all vaccinated individuals. -Less favourable outcomes were observed in rituximab-treated patients regardless of vaccination status but based on few events. Since the onset of the COVID-19 pandemic, researchers have focused on identifying particular risk groups in terms of contracting SARS-CoV2, being hospitalised with COVID-19 and of experiencing a severe outcome, e.g., death, during COVID-19 hospitalisation. In several studies, patients with rheumatoid arthritis (RA) have been associated with an increased risk of being hospitalised with COVID-19 when compared with the general population or non-RA individuals (1-7), but results have not been uniform when looking at the risk of contracting SARS-CoV2 (8) (9) (10) (11) nor of having a severe outcome following hospitalisation (1, 11, 12) . In Denmark, a national vaccination strategy was implemented at the end of December 2020. The BNT162b2 (Pfizer BioNTech) and mRNA-1273 (Moderna) vaccines, both mRNA vaccines (13, 14) , were the first available vaccines in Denmark. Considering the immunologic dysregulation intrinsic to RA and the immunosuppressive treatments frequently adopted in these patients, some concerns have arisen regarding vaccine efficacy and safety in this population. In the phase three trials of BNT162b2 by Polack et al. (15) and mRNA-1273 by Baden et al. (14) , treatment with immunosuppressive therapy was an exclusion criterion and only few participants suffered from rheumatic disease. Whether the excess risk of COVID-19 hospitalisation associated with RA has disappeared after introduction of vaccinations, and if patients with RA in general or patients treated with certain disease-modifying antirheumatic drugs (DMARDs) should be prioritised for potential future booster shots is yet to be investigated on a nationwide scale. Thus, the aims of this study were to estimate the incidence of hospitalisation due to COVID-19 in patients with RA according to vaccination status compared with matched individuals from the general population; and as a secondary outcome, the risk of a first-time COVID-19 infection. Lastly, we estimated the incidence of the primary and secondary outcomes in a subgroup analysis of patients with RA treated with various DMARD regimens. This was a population-based observational matched cohort study investigating the incidence of COVID-19 hospitalisation in patients with RA from 1 January to 5 October 2021 via linkage of several Danish nationwide registers. Secondarily, we studied the incidence of a first-time positive SARS-CoV2 PCR-test; and, for patients with RA, we explored the rate of COVID-19 hospitalisation and mortality according to vaccination status and type of DMARD treatment. During the study period, the dominant SARS-CoV2 strains were Alpha (start of study period to end of June 2021) and Delta (1 July to end of 5 October 2021)(16,17). According to Danish legislation, no ethics approval is needed for register-based studies. The study has been approved by the Data Protection Committee of Northern Jutland, Denmark (2020-032). The Danish Civil Registration System contains information on all residents of Denmark including the unique civil registration number, which enables linkage between registers (18) . The Civil Registration System was used to identify all Danish individuals above 18 years old and alive on 1 January 2021, and to obtain information on age, sex, and vital status. DANBIO is a nationwide clinical quality register for inflammatory arthritis, including RA, and used in routine care by all departments of rheumatology in Denmark. The positive predictive value (PPV) of an RA diagnosis in DANBIO has been estimated to 96% (19) . The Danish Vaccination Register (DDV) was used to obtain information on the exact type and date of all first and second COVID-19 vaccine doses (20) . From The National Surveillance at The State Serum Institute, Denmark, information was obtained on the date of all first positive PCR-tests for SARS-CoV2 in Denmark during the study period. The Danish National Patient Register (DNPR) is a nationwide administrative register of contacts in the secondary and tertiary health care sector (21) . The Danish National Prescription Registry (NPR) holds information on date of redemption and Anatomical Therapeutic Chemical Classification System (ATC) codes on all prescriptions redeemed at pharmacies in Denmark (22) . Patients with RA were identified in DANBIO with ICD-10 codes M05 and M06 and included in the study if registered before 1 May 2020 and alive on 1 January 2021. The vaccination history of each patient with RA was obtained through linkage with the DDV, thereby obtaining information on the date and exact type of first and second vaccination against COVID-19. By 1 January 2021, all patients with RA were unvaccinated and, corresponding to this date, were matched with up to 20 unvaccinated individuals from the general population with no history of inflammatory rheumatic disease. Besides vaccination status, i.e., being unvaccinated, matching parameters were year of birth and sex. Unvaccinated patients and matched comparators were then followed from 1 January 2021 to the date of first COVID-19 hospitalisation, death, date of first vaccination, or 5 October 2021, whichever occurred first. Those patients who received a first vaccination and had, at that point, not been hospitalised with COVID-19, were then matched with 20 individuals from the general population that also had no history of COVID-19 hospitalisation. The matching parameters were once again vaccination Page 6 of 36 Rheumatology 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 status (now partially vaccinated), year of birth, sex, In all vaccination status strata, individuals were excluded for further follow-up at time of their first COVID-19 hospitalisation. Thus, a patient or comparator could not contribute multiple outcomes in one vaccination stratum, nor could they progress to and contribute with follow-up to the next vaccination status if they had been hospitalised. The primary outcome of COVID-19 hospitalisation was identified through linkage with DNPR Chronic lung disease, cardiovascular disease, diabetes mellitus type I and II, chronic kidney disease, and cancer (except non-melanoma skin cancer) were a priori comorbidities of interest and were identified using ICD-10 codes in the DNPR and/or redeemed prescriptions registered in the NPR of available at Rheumatology online). For descriptive purposes, information on redeemed prescriptions of conventional synthetic DMARD (csDMARD) and prednisolone within 1 year prior to start of follow-up, was obtained from NPR using ATC-codes (Supplementary Table S1 ). For biological DMARDs (bDMARD) including TNF-inihibitors, rituximab, interleukin-6 inhibitors, and abatacept, as well as certain csDMARDs, SKS-procedure codes in the DNPR were used to obtain information on date of administration for these drugs in the year leading up to start of follow-up (Supplementary Table S1 ). Unfortunately, neither DNPR nor NPR held information on administration of leflunomide or JAK-inhibitor treatment during the study period. Age-and sex standardised incidence rates (IRs) of hospitalisation per 1000 person years (PY) were estimated with 95% confidence intervals (95%CI). In each vaccination status stratum, the incidence of hospitalisation with COVID-19 in patients with RA was compared with their matched comparators, using a stratified cause-specific Cox-regression taking into account the competing risk of death (24). RA was considered the main exposure variable and stratification 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 was done by matched pairs. Additionally, a comorbidity-adjusted model was made (comorbidities: chronic lung disease, diabetes mellitus, cardiovascular disease, chronic kidney disease, and cancer) and hazard ratios (HRs) for COVID-19 hospitalisation and the competing event of death were presented, both with their corresponding 95% CI. The proportional hazards assumption was evaluated by plotting the scaled Schoenfeld residuals against time. To illustrate the overall absolute risk of first COVID-19 hospitalisation for the RA and comparator groups in the respective vaccination states while taking into account the competing risk of death, the Aalen-Johansen estimated cumulative incidence (in %) was plotted as a function of follow-up time. The x-axis was from time 0 to the 3 rd quartile of follow-up within each vaccination stratum. Following exclusion of patients with a history of COVID-19 prior to start of follow-up, IRs, and cause-specific HR for a first-time positive SARS-CoV2 PCR test were estimated for patients with RA and comparators. Data management and statistical analyses were performed in R 4.0.3. Cause-specific Cox models were fitted using the 'riskRegression' package, and the Aalen-Johansen cumulative incidence functions were estimated using the 'prodlim' package (25,26). The model specifications are shown in the Supplementary Data S1, available at Rheumatology online. Considering only patients with RA, the three vaccination strata were split by exposure to DMARDs as ('Any bDMARD treatment except rituximab', 'rituximab', 'csDMARD treatment only' and 'no DMARD treatment'). Patients that had received multiple types of bDMARDs in the year leading up to start of follow-up was allocated to 'Any bDMARD'. The IRs and HRs for first-time infection and hospitalisation with COVID-19, respectively, were estimated The Cox- Lastly, for exploratory purposes, among rituximab treated patients with RA, we calculated the mean time since last infusion at start of follow-up (date of vaccination) in those with and without COVID-19 infection. A sufficient vaccine response is not expected until 7-14 days post-vaccination. Thus, a potential interaction between exposure group (RA vs matched comparators) and time since follow-up was investigated, by calculating HRs for the days 0 to 10 and 10+ post-vaccination. This analysis was repeated using cut-off values for follow-up with days 0 to 14 and 14+. A total of 28 447 SARS-CoV2 unvaccinated patients with RA started follow-up on 1 January 2021. The median age was 67.7 years, 71.3% were women, 68% were treated with csDMARD and 23.7% treated with a bDMARD ( 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 the first vaccination, the groups were followed for a median of 28 and 30 days and had IRs of COVID-19 hospitalisation of 5.5 (95%CI 3.0 to 10.0) and 2.2 (95%CI 1.8 to 2.7) per 1000 PY, respectively ( Table 2 ). In Denmark, non-mRNA vaccines were excluded from the state-sponsored COVID (Table 3 ). Among vaccinated, there was no difference in incidence of first-time SARS-CoV2 infection ( Table 3 ). In patients with RA, bDMARD treated were younger and a higher proportion was women (Table 4 ). The rituximab treated group had higher proportions of patients with a history of cancer and prednisolone users. For unvaccinated, patients treated with 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 (37) . With regards to the specific absolute and relative incidence rates in the present study, it is important to remember two factors putting the results in context: first, the absolute risk of hospitalisation may be considered low, but it is worth noting that Denmark has had one of the lowest SARS-CoV2 infection rates in Europe during the pandemic, and the study period 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 specifically covered here was when the infection rates were at their lowest from 2020 to 2021.Thus, the absolute risks do not transfer to other countries with different, and likely higher background rates, whereas the relative rates are relevant and of interest to different RA populations in other countries. Second, a Danish study showed that patients with RA were more likely to self-isolate and take stronger measures of social distancing even when federal general restrictions were abandoned. Thus, the HRs for both infection and hospitalisation may be underestimating the true biological difference (38) . We believe that the totality of findings in the existing literature and the results in the present study, constitute a strong argument for prioritising patients with RA high for future booster shots. There are important limitations that needs mentioning: First, we did not have access to information on incident patients with RA for the period of May 2020 to January 2021. In Denmark, the incidence of RA is roughly 1700 per year, and therefore about 900 patients may have been misclassified as non-RA. The impact of this in a 1:20 general population matching setting is expected to be minimal. Another limitation is that we did not have access to register information on leflunomide and JAK-inhibitor treatment, of which namely the latter could have been of interest to study (7,39). Some of our subgroup analyses were hampered by a low number of events. Lastly, the use of diagnoses in an administrative register could lead to misclassification. However, the high validity of the COVID-19 outcomes is very reassuring, and although we can only speculate, we have very little reason not to think that the sensitivity of these ICD-10 codes is also high given the registration process and incentive to register in DNPR (23) . There are also strengths to our study. Importantly, the validity of the RA diagnosis in DANBIO is very high (19) , thus ensuring that the risk estimates provided are in fact for a true RA 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 population. Also, the vaccination data from DDV has a high validity and carries detailed information, enabling us to match on both temporality as well as exact type of vaccine at each shot. In conclusion, the results of this study confirm the observed increased risk of hospitalisation with COVID-19 in the pre-vaccination era in patients with RA compared with non-RA individuals. Further, although the absolute risk was low among fully vaccinated individuals, the relative incidence rate has remained increased in patients with RA compared with matched individuals from the general population, but nonetheless underlines the importance of vaccination . 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 Incidence and severeness of COVID-19 hospitalization in patients with inflammatory rheumatic disease: A nationwide cohort study from Denmark Impact of the COVID-19 pandemic on morbidity and mortality in patients with inflammatory joint diseases and in the general population: A nationwide Swedish cohort study Association between previous rheumatoid arthritis and COVID-19 and its severity: a nationwide cohort study in South Korea COVID-19 in patients with rheumatic disease in Hubei province, China: a multicentre retrospective observational study Susceptibility and severity of COVID-19 in patients treated with bDMARDS and tsDMARDs: A population-based study SARS-CoV-2 Infection and COVID-19 Outcomes in Rheumatic Disease: A Systematic Literature Review And Meta-Analysis Clinical outcomes of COVID-19 in patients with rheumatic diseases: A systematic review and meta-analysis of global data Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine The Danish Civil Registration System as a tool in epidemiology Validity and completeness of rheumatoid arthritis diagnoses in the nationwide DANBIO clinical register and the Danish national patient registry The Danish vaccination register The Danish National patient registry: A review of content, data quality Data resource profile: The Danish national prescription registry Positive predictive Rheumatoid Arthritis Effect of immunosuppression on the immunogenicity of mrna vaccines to sars-cov-2 a prospective cohort study Glucocorticoids and B Cell Depleting Agents Substantially Impair Immunogenicity of mRNA Vaccines to SARS-CoV-2. medRxiv Rituximab Infusion Timing, Cumulative Dose, and Hospitalization for COVID-19 in Persons with Multiple Sclerosis in Sweden Selfprotection strategies and health behaviour in patients with inflammatory rheumatic diseases during the COVID-19 pandemic: Results and predictors in more than 12 000 patients with inflammatory rheumatic diseases followed in the Danish DANBIO registry Serum Institut for carrying out laboratory analysis, registration, and release of the national SARS-CoV-2 surveillance data use in the present study. Further, the authors wish to thank all the Danish departments of rheumatology for reporting to the DANBIO register.Abbreviations: TNFi, tumour necrosis factor inhibitor; IL6, interleukin 6; csDMARD, conventional synthetic DMARD; IQR, interquartile range; PY, person years; HR, hazard ratio. b Severe outcome defined as the composite of either acute respiratory distress syndrome, admission to an intensive care unit, and/or death